Skip to main content

Table 5 Highest grade of adverse events (AEs) felt possibly, likely or almost certainly caused by injection of vaccine

From: Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

Grade

All (N = 42)

TCV (n = 24)

DCV (n = 18)

Grade 0

6 (14%)

2 (8%)

4 (22%)

Grade 1

16 (38%)

5 (21%)

11 (61%)

Grade 2

19 (45%)

17 (71%)

2 (11%)

Grade 3

1 (2%)

0

1 (5%)

Grade 4

0

0

0

  1. TCV tumor cell vaccine, DCV dendritic cell vaccine
Back to article page